CLRB
Cellectar Biosciences, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 5,
"returned": 4,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "a190bac2-ecb9-4def-ac6e-438b51f994b3",
"title": "Earnings call: Cellectar Biosciences outlines robust WM market strategy By Investing.com",
"description": "Earnings call: Cellectar Biosciences outlines robust WM market strategy",
"keywords": "",
"snippet": "Cellectar Biosciences (NASDAQ: ) has reported its first-quarter financial results and provided updates on its corporate strategy, with a particular focus on the...",
"url": "https://www.investing.com/news/stock-market-news/earnings-call-cellectar-biosciences-outlines-robust-wm-market-strategy-93CH-3440203",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEC0409P_L.jpg",
"language": "en",
"published_at": "2024-05-14T18:48:09.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLRB",
"name": "Cellectar Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 69.95489,
"sentiment_score": 0.315886,
"highlights": [
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em> (NASDAQ: ) has reported its first-quarter financial results and provided updates on its corporate strategy, with a particular focus on the Waldenström macroglobulinemia (WM) market.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Key Takeaways\n\n<em>Cellectar</em> <em>Biosciences</em> remains on track for a Q2 data announcement for its fully enrolled study patient population.\n\nThe company plans to submit their NDA to the FDA in the second half of the year, with a six-month review period expected.\n\nA strategic partnership with AON has been announced to treat WM in the community setting.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em> is positioning itself to be a significant player in the WM market, with strategic plans in place for commercialization and distribution of its product, iopofosine.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nInvestingPro Insights\n\n<em>Cellectar</em> <em>Biosciences</em> (CLRB) has shared its strategic intentions and financial outcomes in the WM market, emphasizing the potential of iopofosine. As investors and stakeholders consider the company's prospects, it is crucial to examine key financial metrics and insights that could impact its trajectory.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "For those seeking further insights, there are additional InvestingPro Tips available for <em>Cellectar</em> <em>Biosciences</em>, which can be accessed at https://www.investing.com/pro/CLRB.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nFull transcript - Cellectar Biosci (CLRB) Q1 2024:\n\nOperator: Good morning and welcome to <em>Cellectar</em> <em>Biosciences</em> First Quarter 2024 Earnings Call. Today's call is being recorded.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings call: <em>Cellectar</em> <em>Biosciences</em> outlines robust WM market strategy By Investing.com",
"sentiment": 0.34,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "05f8b16d-c2a9-42cd-ade7-e08060ccec95",
"title": "Cellectar Biosciences, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:CLRB)",
"description": "The following slide deck was published by Cellectar Biosciences, Inc.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/article/4693151-cellectar-biosciences-inc-2024-q1-results-earnings-call-presentation",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-05-14T17:07:05.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLRB",
"name": "Cellectar Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 203.07138,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em>, <em>Inc</em>. 2024 Q1 - Results - Earnings Call Presentation (<em>NASDAQ:CLRB</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "91b1c477-3cfd-4665-a7ca-4d0bd870a45e",
"title": "Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript",
"description": "Cellectar Biosciences, Inc. (NASDAQ:NASDAQ:CLRB) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ETCompany ParticipantsJames Caruso - President and...",
"keywords": "",
"snippet": "Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET\n\nCompany Participants\n\nJames Caruso - President and Chief Exe...",
"url": "https://seekingalpha.com/article/4693148-cellectar-biosciences-inc-clrb-q1-2024-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-05-14T17:05:17.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLRB",
"name": "Cellectar Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 167.02005,
"sentiment_score": 0.1774,
"highlights": [
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:CLRB</em>) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET\n\nCompany Participants\n\nJames Caruso - President and Chief Executive Officer\n\nAndrei Shustov - Senior Vice President, Medical\n\nJarrod Longcor - Chief Operating Officer\n\nShane Lea - Chief Commercial Officer\n\nChad Kolean - Chief Financial Officer\n\nConference Call Participants\n\nAhu Demir",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "- Ladenburg Thalmann\n\nJeff Jones - Oppenheimer\n\nJonathan Aschoff - ROTH MKM\n\nOperator\n\nGood morning and welcome to <em>Cellectar</em> <em>Biosciences</em> First Quarter 2024 Earnings Call.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em>, <em>Inc</em>. (CLRB) Q1 2024 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "37242c10-0204-46c5-b36d-3ec124719b1f",
"title": "Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update By Investing.com",
"description": "Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update",
"keywords": "",
"snippet": "Management to host a conference call today at 8:30 am ET\n\nWM pivotal study data to be announced in June\n\nFLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Ce...",
"url": "https://www.investing.com/news/press-releases/cellectar-biosciences-reports-financial-results-for-q1-2024-and-provides-a-corporate-update-93CH-3438977",
"image_url": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
"language": "en",
"published_at": "2024-05-14T10:52:05.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLRB",
"name": "Cellectar Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 88.639305,
"sentiment_score": -0.1686,
"highlights": [
{
"highlight": "., May 14, 2024 (GLOBE NEWSWIRE) -- <em>Cellectar</em> <em>Biosciences</em>, <em>Inc</em>. (NASDAQ: NASDAQ: ), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update.",
"sentiment": -0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Cellectar</em> <em>Biosciences</em>, Inc.Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations.",
"sentiment": -0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nContacts\n\nMEDIA:Claire LaCagninaBliss Bio [email protected]\n\nINVESTORS:Chad KoleanChief Financial [email protected]\n\n<em>CELLECTAR</em> <em>BIOSCIENCES</em>, <em>INC</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CELLECTAR</em> <em>BIOSCIENCES</em>, <em>INC</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em> Reports Financial Results for Q1 2024 and Provides a Corporate Update By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "fb67a52c-7526-49d3-bee7-d4d4e886a3cd",
"title": "Cellectar Biosciences GAAP EPS of -$0.74 misses by $0.18 (NASDAQ:CLRB)",
"description": "Cellectar Biosciences reports Q1 financial results, with a GAAP EPS of -$0.74, missing expectations by $0.18.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4105660-cellectar-biosciences-gaap-eps-of-0_74-misses-0_18",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-05-14T10:44:49.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "CLRB",
"name": "Cellectar Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 116.39957,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "<em>Cellectar</em> <em>Biosciences</em> GAAP EPS of -$0.74 misses by $0.18 (<em>NASDAQ:CLRB</em>)",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "CLRB",
"total_documents": 5,
"sentiment_avg": 0.01967719793319702
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us